Myeloperoxidase levels are not associated with carotid atherosclerosis progression in patients with familial hypercholesterolemia

Atherosclerosis

Volumn 197, Issue 2, 2008, Pages 916-921

  Meuwese, Marijn C ^a   Trip, Mieke D ^a   van Wissen, Sanne ^a   van Miert, Joram N I ^a   Kastelein, John J P ^a   Stroes, Erik S G ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Atherosclerosis; Familial hypercholesterolemia; Intima media thickness; Myeloperoxidase; Statin

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; C REACTIVE PROTEIN; CHLOROTYROSINE; HEPARIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYELOPEROXIDASE; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL; TYROSINE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CAROTID ARTERY DISEASE; CAROTID ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG POTENCY; ENZYME BLOOD LEVEL; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; FOLLOW UP; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS;

ADULT; CAROTID ARTERY DISEASES; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; PEROXIDASE; TUNICA INTIMA; TUNICA MEDIA;

EID: 40949111792     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2007.08.011     Document Type: Article

References (35)

1. Baigent C., Keech A., Kearney P.M., et al. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
2. Takemoto M., and Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 21 (2001) 1712-1719
3. Akdim F., van Leuven S.I., Kastelein J.J.P., and Stroes E.S.G. Pleiotropic effects of statins: stabilization of the vulnerable atherosclerotic plaque?. Curr Pharm Des 13 (2007) 1003-1012
4. Ridker P.M., Cannon C.P., Morrow D., et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352 (2005) 20-28
5. Ray K.K., Cannon C.P., McCabe C.H., et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 46 (2005) 1405-1410
6. Klebanoff S.J., Waltersdorph A.M., and Rosen H. Antimicrobial activity of myeloperoxidase. Methods Enzymol 105 (1984) 399-403
7. Podrez E.A., Schmidt D., Hoff H.F., and Hazen S.L. Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J Clin Invest 103 (1999) 1547-1560
8. Yang C.Y., Gu Z.W., Yang M., et al. Selective modification of apoB-100 in the oxidation of low density lipoproteins by myeloperoxidase in vitro. J Lipid Res 40 (1999) 686-698
9. Zheng L., Nukuna B., Brennan M.L., et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 114 (2004) 529-541
10. Bergt C., Pennathur S., Fu X., et al. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc Natl Acad Sci USA 101 (2004) 13032-13037
11. Eiserich J.P., Baldus S., Brennan M.L., et al. Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science 296 (2002) 2391-2394
12. Daugherty A., Dunn J.L., Rateri D.L., and Heinecke J.W. Myeloperoxidase: a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 94 (1994) 437-444
13. Hazell L.J., Arnold L., Flowers D., et al. Presence of hypochlorite-modified proteins in human atherosclerotic lesions. J Clin Invest 97 (1996) 1535-1544
14. Sugiyama S., Okada Y., Sukhova G.K., et al. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol 158 (2001) 879-891
15. Sugiyama S., Kugiyama K., Aikawa M., et al. Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression: involvement of myeloperoxidase-mediated oxidant in plaque erosion and thrombogenesis. Arterioscler Thromb Vasc Biol 24 (2004) 1309-1314
16. Meuwese M.C., Stroes E.S., Hazen S.L., et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol 50 (2007) 159-165
17. Zhang R., Brennan M.L., Fu X., et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 286 (2001) 2136-2142
18. Baldus S., Rudolph V., Roiss M., et al. Heparins increase endothelial nitric oxide bioavailability by liberating vessel-immobilized myeloperoxidase. Circulation 113 (2006) 1871-1878
19. Brennan M.L., Penn M.S., Van Lente F., et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 349 (2003) 1595-1604
20. Baldus S., Heeschen C., Meinertz T., et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 108 (2003) 1440-1445
21. Smilde T.J., Trip M.D., Wollersheim H., et al. Rationale design and baseline characteristics of a clinical trial comparing the effects of robust versus conventional cholesterol lowering and intima media thickness in patients with familial hypercholesterolemia. The atorvastatin versus simvastatin on atherosclerosis progression (ASAP) study. Clin Drug Invest 20 (2001) 67-79
22. Smilde T.J., van Wissen S., Wollersheim H., et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP); a prospective, randomised, double-blind trial. Lancet 357 (2001) 577-581
23. Van Wissen S., Trip M.D., Smilde T.J., et al. Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy. Atherosclerosis 165 (2002) 361-366
24. Kalantar-Zadeh K., Brennan M.L., and Hazen S.L. Serum myeloperoxidase and mortality in maintenance hemodialysis patients. Am J Kidney Dis 48 (2006) 59-68
25. Tang W.H., Brennan M.L., Philip K., et al. Plasma myeloperoxidase levels in patients with chronic heart failure. Am J Cardiol 98 (2006) 796-799
26. Kumar A.P., and Reynolds W.F. Statins downregulate myeloperoxidase gene expression in macrophages. Biochem Biophys Res Commun 331 (2005) 442-451
27. Zhou T., Zhou S.H., Qi S.S., et al. The effect of atorvastatin on serum myeloperoxidase and CRP levels in patients with acute coronary syndrome. Clin Chim Acta 368 (2006) 168-172
28. Hazen S.L., Crowley J.R., Mueller D.M., and Heinecke J.W. Mass spectrometric quantification of 3-chlorotyrosine in human tissues with attomole sensitivity: a sensitive and specific marker for myeloperoxidase-catalyzed chlorination at sites of inflammation. Free Radic Biol Med 23 (1997) 909-916
29. Pennathur S., Bergt C., Shao B., et al. Human atherosclerotic intima and blood of patients with established coronary artery disease contain high density lipoprotein damaged by reactive nitrogen species. J Biol Chem 279 (2004) 42977-42983
30. Shishehbor M.H., Brennan M.L., Aviles R.J., et al. Statins promote potent systemic antioxidant through specific inflammatory pathways. Circulation 108 (2003) 426-431
31. Vita J.A., Brennan M.L., Gokce N., et al. Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation 110 (2004) 1134-1139
32. Mason R.P., Walter M.F., Day C.A., and Jacob R.F. Active metabolite of atorvastatin inhibits membrane cholesterol domain formation by an antioxidant mechanism. J Biol Chem 281 (2006) 9337-9345
33. Wassmann S., Laufs U., Müller K., et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 22 (2002) 300-305
34. McMillen T.S., Heinecke J.W., and LeBoeuf R.C. Expression of human myeloperoxidase by macrophages promotes atherosclerosis in mice. Circulation 111 (2005) 2798-2804
35. Exner M., Minar E., Mlekusch W., et al. Myeloperoxidase predicts progression of carotid stenosis in states of low high-density lipoprotein cholesterol. J Am Coll Cardiol 47 (2006) 2212-2218